TSE:4503Pharmaceuticals
How Positive PADCEV Keytruda Phase 3 Perioperative Data At Astellas Pharma (TSE:4503) Has Changed Its Investment Story
Pfizer and Astellas Pharma recently reported positive Phase 3 EV-304 results showing PADCEV plus Keytruda cut the risk of tumor recurrence, progression or death in cisplatin-eligible muscle-invasive bladder cancer patients versus standard gemcitabine and cisplatin.
The combination also achieved higher event-free survival, overall survival and pathological complete response rates with a consistent safety profile, potentially reinforcing PADCEV’s role in earlier-stage bladder cancer...